N I, Kp S, R J, Mg R
BMC Health Serv Res. 2025; 25(1):166.
PMID: 39875957
PMC: 11773872.
DOI: 10.1186/s12913-024-12139-w.
Kabiri N, Hajebrahimi S, Rahmani P, Tavani F, Saghaleini S, Soofiyani S
Health Sci Rep. 2024; 7(12):e70277.
PMID: 39698521
PMC: 11652391.
DOI: 10.1002/hsr2.70277.
Toroitich A, Armitage R, Tanna S
BMC Public Health. 2024; 24(1):2561.
PMID: 39300437
PMC: 11414318.
DOI: 10.1186/s12889-024-20036-4.
Rotimi K, Fagbemi B, Omole G, Biambo A, Ibinaiye T, Iwegbu A
BMC Health Serv Res. 2024; 24(1):952.
PMID: 39164692
PMC: 11337761.
DOI: 10.1186/s12913-024-11343-y.
Putri R, Ikawati Z, Rahmawati F, Yasin N
Curr Drug Saf. 2024; 19(3):317-331.
PMID: 38989832
PMC: 11327747.
DOI: 10.2174/0115748863276456231016062628.
Exploring pharmacovigilance practices and knowledge among healthcare professionals: A cross-sectional multicenter study.
Hayek A, Sridhar S, Rabbani S, Shareef J, Wadhwa T
SAGE Open Med. 2024; 12:20503121241249908.
PMID: 38725923
PMC: 11080773.
DOI: 10.1177/20503121241249908.
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System.
Sorbara E, Barbieri M, Russo G, Cicala G, Spina E
BioDrugs. 2024; 38(2):275-285.
PMID: 38402495
DOI: 10.1007/s40259-024-00651-8.
Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers.
Christ P, Dubrall D, Schmid M, Sachs B
Drug Saf. 2023; 46(12):1363-1379.
PMID: 37987966
PMC: 10684666.
DOI: 10.1007/s40264-023-01355-8.
Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database.
Gustafsson M, Matos C, Joaquim J, Scholl J, van Hunsel F
Drug Saf. 2023; 46(11):1133-1148.
PMID: 37824028
DOI: 10.1007/s40264-023-01351-y.
Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System.
Veliscu E, Liguori V, Anatriello A, Maniscalco G, Cantone A, Di Costanzo L
Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37630986
PMC: 10459297.
DOI: 10.3390/ph16081071.
A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database.
Rafaniello C, Liguori V, Zinzi A, Gaio M, Falco A, Di Costanzo L
Biomedicines. 2023; 11(8).
PMID: 37626659
PMC: 10452324.
DOI: 10.3390/biomedicines11082162.
Defining the awareness and attitude of the clinicians through pharmacovigilance in Turkey.
Aydin O, Aydin S, Guney H
World J Clin Cases. 2023; 11(20):4865-4873.
PMID: 37583988
PMC: 10424053.
DOI: 10.12998/wjcc.v11.i20.4865.
The specialized competency framework for community pharmacists (SCF-CP) in Lebanon: validation and evaluation of the revised version.
Sakr F, Akel M, Sacre H, Haddad C, Tawil S, Safwan J
J Pharm Policy Pract. 2023; 16(1):77.
PMID: 37344915
PMC: 10283199.
DOI: 10.1186/s40545-023-00585-6.
Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework.
Shafei L, Mekki L, Maklad E, Alhathal T, Ghanem R, Almalouf R
Int J Clin Pharm. 2023; 45(4):801-813.
PMID: 37247158
PMC: 10366238.
DOI: 10.1007/s11096-023-01591-z.
Healthcare professionals' awareness, attitudes and practices towards pharmacovigilance and spontaneous adverse drug reaction reporting in Jazan Province, Saudi Arabia: A survey study.
Alqahtani S, Ahmad S, Alam N, Syed N, Syed M, Khardali A
Saudi Pharm J. 2023; 31(6):979-988.
PMID: 37234340
PMC: 10205759.
DOI: 10.1016/j.jsps.2023.04.021.
Evaluation of health care professionals' knowledge, attitudes, practices and barriers to pharmacovigilance and adverse drug reaction reporting: A cross-sectional multicentral study.
Khan Z, Karatas Y, Hamid S
PLoS One. 2023; 18(5):e0285811.
PMID: 37224133
PMC: 10208525.
DOI: 10.1371/journal.pone.0285811.
Impact of educational interventions on pharmacovigilance and adverse drug reaction reporting by resident doctors and faculty members: A prospective comparative study.
Belhekar M, Dhorajiwala S, Krishnamurthy B
Perspect Clin Res. 2023; 14(1):32-38.
PMID: 36909212
PMC: 10003584.
DOI: 10.4103/picr.picr_198_21.
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana.
Yawson A, Abekah-Nkrumah G, Okai G, Ofori C
Ther Adv Drug Saf. 2022; 13:20420986221116468.
PMID: 35966898
PMC: 9364224.
DOI: 10.1177/20420986221116468.
Knowledge, attitude and practice of hospital pharmacists towards pharmacovigilance and adverse drug reaction reporting in Najran, Saudi Arabia.
Alshabi A, Shaikh M, Shaikh I, Alkahtani S, Aljadaan A
Saudi Pharm J. 2022; 30(7):1018-1026.
PMID: 35903528
PMC: 9315274.
DOI: 10.1016/j.jsps.2022.04.014.
The development of a pharmacovigilance system in Bahrain.
Abdulrasool Z
Saudi Pharm J. 2022; 30(6):825-841.
PMID: 35812145
PMC: 9257873.
DOI: 10.1016/j.jsps.2022.03.009.